Published in Clin Cancer Res on October 14, 2010
Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy. Antioxid Redox Signal (2012) 2.05
Preventing Age-Related Decline of Gut Compartmentalization Limits Microbiota Dysbiosis and Extends Lifespan. Cell Host Microbe (2016) 1.51
The microRNAs, MiR-31 and MiR-375, as candidate markers in Barrett's esophageal carcinogenesis. Genes Chromosomes Cancer (2012) 1.06
MicroRNA involvement in esophageal carcinogenesis. Curr Opin Pharmacol (2011) 0.95
MicroRNA 223 is upregulated in the multistep progression of Barrett's esophagus and modulates sensitivity to chemotherapy by targeting PARP1. Clin Cancer Res (2013) 0.93
Molecular mechanisms of Barrett's esophagus. Dig Dis Sci (2011) 0.89
MiRNA-Related SNPs and Risk of Esophageal Adenocarcinoma and Barrett's Esophagus: Post Genome-Wide Association Analysis in the BEACON Consortium. PLoS One (2015) 0.84
Prognostic significance of microRNA-375 downregulation in solid tumors: a meta-analysis. Dis Markers (2014) 0.83
Interweaving microRNAs and proinflammatory cytokines in gastric mucosa with reference to H. pylori infection. J Clin Immunol (2011) 0.82
Pancreatic cancer tumour initiating cells: the molecular regulation and therapeutic values. J Cell Mol Med (2012) 0.82
Targeting chemokine pathways in esophageal adenocarcinoma. Cell Cycle (2014) 0.79
CXC and CC chemokines as angiogenic modulators in nonhaematological tumors. Biomed Res Int (2014) 0.78
Clinical impact of tumor-infiltrating inflammatory cells in primary small cell esophageal carcinoma. Int J Mol Sci (2014) 0.77
Prognostic role of microRNAs in human gastrointestinal cancer: A systematic review and meta-analysis. Oncotarget (2017) 0.77
Circulating miRNA profile in esophageal adenocarcinoma. Am J Cancer Res (2016) 0.76
The inflammatory cytokine interleukin-23 is elevated in lung cancer, particularly small cell type. Contemp Oncol (Pozn) (2016) 0.75
Macrophage subtype predicts lymph node metastasis in oesophageal adenocarcinoma and promotes cancer cell invasion in vitro. Br J Cancer (2015) 0.75
Emerging therapeutic targets in esophageal adenocarcinoma. Oncotarget (2016) 0.75
Cancer Recurrence After Esophagectomy: Impact of Postoperative Infection in Propensity-Matched Cohorts. Ann Thorac Surg (2016) 0.75
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
Cancer statistics, 2007. CA Cancer J Clin (2007) 53.49
MicroRNA signatures in human cancers. Nat Rev Cancer (2006) 46.29
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 24.54
Esophageal cancer. N Engl J Med (2003) 15.23
Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol (2002) 14.75
Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med (2005) 12.64
Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA (1991) 11.53
The Vienna classification of gastrointestinal epithelial neoplasia. Gut (2000) 9.39
Annexins: from structure to function. Physiol Rev (2002) 6.78
Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer (2004) 4.43
Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell (2006) 4.33
Cancer: an inflammatory link. Nature (2004) 3.88
Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res (2001) 3.23
MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res (2009) 3.03
Implications of micro-RNA profiling for cancer diagnosis. Oncogene (2006) 2.01
Diversity in the oesophageal phenotypic response to gastro-oesophageal reflux: immunological determinants. Gut (2002) 1.92
Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation. Cancer Res (2005) 1.90
The melanoma differentiation associated gene mda-7 suppresses cancer cell growth. Proc Natl Acad Sci U S A (1996) 1.73
The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24. J Immunol (2002) 1.69
Association of inflammation-related and microRNA gene expression with cancer-specific mortality of colon adenocarcinoma. Clin Cancer Res (2009) 1.67
Columnar mucosa and intestinal metaplasia of the esophagus: fifty years of controversy. Ann Surg (2000) 1.63
Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier. J Natl Cancer Inst (2007) 1.58
Focus on Barrett's esophagus and esophageal adenocarcinoma. Cancer Cell (2004) 1.57
Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Gastroenterol (2005) 1.56
Loss of annexin 1 correlates with early onset of tumorigenesis in esophageal and prostate carcinoma. Cancer Res (2000) 1.50
Prognostic significance of differentially expressed miRNAs in esophageal cancer. Int J Cancer (2011) 1.43
CDX1 is an important molecular mediator of Barrett's metaplasia. Proc Natl Acad Sci U S A (2005) 1.34
Translating cancer genomics into clinical oncology. N Engl J Med (2004) 1.33
Expression of annexin A1 in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Clin Cancer Res (2006) 1.21
Molecular target-based therapy of pancreatic cancer. Cancer Res (2006) 1.12
Clinical and experimental approaches to the pathophysiology of interleukin-18 in cancer progression. Cancer Metastasis Rev (2006) 1.11
Elevated tumour interleukin-1beta is associated with systemic inflammation: A marker of reduced survival in gastro-oesophageal cancer. Br J Cancer (2006) 1.08
Comprehensive characterization of annexin I alterations in esophageal squamous cell carcinoma. Clin Cancer Res (2004) 1.05
IL-22-mediated tumor growth reduction correlates with inhibition of ERK1/2 and AKT phosphorylation and induction of cell cycle arrest in the G2-M phase. J Immunol (2006) 1.01
A pro-inflammatory genotype predisposes to Barrett's esophagus. Carcinogenesis (2008) 0.98
Production of interleukin-1 and interleukin-6 by human keratinocytes and squamous cell carcinoma cell lines. J Invest Dermatol (1991) 0.95
Serum interleukin-12 and interleukin-18 levels as a tumor marker in patients with esophageal carcinoma. Cancer Lett (2004) 0.93
Expression and prognostic significance of immunoregulatory molecules in esophageal cancer. Int J Cancer (1997) 0.89
Interleukin-21 is a T-helper cytokine that regulates humoral immunity and cell-mediated anti-tumour responses. Immunology (2004) 0.88
Cytokine mRNA expression patterns in human esophageal cancer cell lines. J Interferon Cytokine Res (1995) 0.88
Advances in the treatment of esophageal carcinoma. Gastroenterologist (1997) 0.85
Expression of interleukin-21 and -23 in human esophageal tumors produced antitumor effects in nude mice. Anticancer Res (2004) 0.84
Melanoma differentiation-associated gene-7/IL-24 gene enhances NF-kappa B activation and suppresses apoptosis induced by TNF. J Immunol (2004) 0.83
Negative feedback regulation of IFN-gamma pathway by IFN regulatory factor 2 in esophageal cancers. Cancer Res (2008) 0.83
Molecular mechanisms in Barrett's metaplasia and its progression. Semin Oncol (2007) 0.79
A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A (2006) 40.09
Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell (2006) 23.59
The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat (2002) 12.39
MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA (2008) 12.26
Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer (2010) 7.39
MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med (2009) 6.13
EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology (2008) 5.53
Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med (2003) 5.45
Radical causes of cancer. Nat Rev Cancer (2003) 5.45
A genetic variation map for chicken with 2.8 million single-nucleotide polymorphisms. Nature (2004) 5.24
Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell (2008) 5.11
Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology (2008) 4.50
KIF5B-RET fusions in lung adenocarcinoma. Nat Med (2012) 4.38
Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell (2006) 4.33
Inflammation and cancer: an ancient link with novel potentials. Int J Cancer (2007) 4.19
EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res (2008) 4.17
Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology (2009) 3.92
Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet (2012) 3.69
MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc Natl Acad Sci U S A (2009) 3.64
Predictive models of molecular machines involved in Caenorhabditis elegans early embryogenesis. Nature (2005) 3.62
Genetic variants and risk of lung cancer in never smokers: a genome-wide association study. Lancet Oncol (2010) 3.49
Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis (2009) 3.40
Gene clustering based on RNAi phenotypes of ovary-enriched genes in C. elegans. Curr Biol (2002) 3.30
The landscape of recombination in African Americans. Nature (2011) 3.06
Essential role for retinoic acid in the promotion of CD4(+) T cell effector responses via retinoic acid receptor alpha. Immunity (2011) 3.06
MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res (2009) 3.03
A cluster of cooperating tumor-suppressor gene candidates in chromosomal deletions. Proc Natl Acad Sci U S A (2012) 2.85
HIF-1alpha induces genetic instability by transcriptionally downregulating MutSalpha expression. Mol Cell (2005) 2.82
Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res (2011) 2.81
p53: traffic cop at the crossroads of DNA repair and recombination. Nat Rev Mol Cell Biol (2005) 2.78
SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity. Cancer Cell (2011) 2.73
The chemical biology of nitric oxide: implications in cellular signaling. Free Radic Biol Med (2008) 2.72
Reprogramming of miRNA networks in cancer and leukemia. Genome Res (2010) 2.65
Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Res (2007) 2.63
Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. J Natl Cancer Inst (2011) 2.61
A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res (2010) 2.59
Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One (2011) 2.57
Integrating interactome, phenome, and transcriptome mapping data for the C. elegans germline. Curr Biol (2002) 2.47
p53 isoforms Delta133p53 and p53beta are endogenous regulators of replicative cellular senescence. Nat Cell Biol (2009) 2.46
Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence. Cancer Res (2008) 2.45
p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity. Cancer Res (2003) 2.40
Sixty-five gene-based risk score classifier predicts overall survival in hepatocellular carcinoma. Hepatology (2012) 2.40
Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology (2002) 2.38
TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. IARC Sci Publ (2004) 2.23
TP53 and liver carcinogenesis. Hum Mutat (2003) 2.23
Temporal and spatial control of nucleophosmin by the Ran-Crm1 complex in centrosome duplication. Nat Cell Biol (2005) 2.15
p53-induced up-regulation of MnSOD and GPx but not catalase increases oxidative stress and apoptosis. Cancer Res (2004) 2.08
Cancer stem cells in the development of liver cancer. J Clin Invest (2013) 2.06
p53-Repressed miRNAs are involved with E2F in a feed-forward loop promoting proliferation. Mol Syst Biol (2008) 2.04
Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proc Natl Acad Sci U S A (2002) 2.04
BLM heterozygosity and the risk of colorectal cancer. Science (2002) 2.03
Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer. Int J Cancer (2011) 2.02
Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways. Cancer Res (2003) 1.97
Ionizing radiation-induced oxidative stress alters miRNA expression. PLoS One (2009) 1.94
MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res (2010) 1.89
MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. J Clin Invest (2013) 1.89
Hypoxic inducible factor 1alpha, extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide. Proc Natl Acad Sci U S A (2004) 1.87
Transcriptional programs following genetic alterations in p53, INK4A, and H-Ras genes along defined stages of malignant transformation. Cancer Res (2005) 1.86
Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell (2013) 1.86
Advances in chemical carcinogenesis: a historical review and prospective. Cancer Res (2008) 1.83
A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry. Nat Genet (2013) 1.82
Functional interaction between BLM helicase and 53BP1 in a Chk1-mediated pathway during S-phase arrest. J Cell Biol (2004) 1.82
The adaptive imbalance in base excision-repair enzymes generates microsatellite instability in chronic inflammation. J Clin Invest (2003) 1.82
The role of cytokines in hepatocellular carcinoma. J Leukoc Biol (2006) 1.75
POT1 and TRF2 cooperate to maintain telomeric integrity. Mol Cell Biol (2005) 1.74
Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma. Clin Cancer Res (2007) 1.73
Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma. Hepatology (2013) 1.73
BLM helicase-dependent transport of p53 to sites of stalled DNA replication forks modulates homologous recombination. EMBO J (2003) 1.71
Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res (2005) 1.70